GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GB Sciences GBLX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

+100.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−$1.4m

FY2015FY2024

Free cash flow

−$975,700

FY2015FY2024

Shareholders' equity

−$5.3m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue———$3.1m$3.1m$3.5m$2.5m———
Research and development$261,550$490,291$821,321$352$1,543$458,790————
Operating income−$1.4m−$1.7m−$1.9m−$2.0m−$12.0m−$13.2m−$17.8m−$8.9m−$7.0m−$8.0m
Net income−$1.4m−$4.1m−$531,000−$3.7m−$12.4m−$23.7m−$23.0m−$9.9m−$6.8m−$7.7m
Diluted earnings per share-0.00-0.01-0.00-0.01-0.04-0.07-0.10-0.08-0.08-0.17

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$103,442$352,323$2.5m$10.8m$14.4m$30.0m$24.0m$13.0m$2.4m$1.5m
Cash and short-term investments$11,991$109,912$233,893$793,040$151,766$227,758$3.6m$2.7m$34,824—
Total liabilities$5.4m$4.8m$4.3m$12.3m$14.4m$12.9m$8.4m$4.6m$4.4m$1.2m
Debt$1.8m$1.4m$1.4m$4.5m$9.4m$8.7m$7.6m$3.9m$2.6m$30,000
Shareholders' equity−$5.3m−$4.4m−$1.8m−$1.5m−$88,494$8.3m$12.7m$8.3m−$1.9m$497,300
Shares outstanding407m403m379m342m281m326m223m128m89m46m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$975,698−$1.5m−$1.9m−$2.2m−$4.5m−$9.2m−$12.2m−$4.5m−$3.6m−$3.5m
Capital spending−$2−$31,650−$200,000−$292,675−$294,159−$10.6m−$3.4m−$3.1m−$881,595−$937,660
Free cash flow−$975,700−$1.6m−$2.1m−$2.5m−$4.8m−$19.8m−$15.7m−$7.5m−$4.4m−$4.5m
Dividends paid—————−$2.86trn————

Latest quarters

By quarter end

Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023
Revenue$97,235$97,235——————
Operating income−$66,591−$66,591−$158,000−$370,000−$369,888−$234,000−$551,000−$265,122
Net income−$100,355−$100,355−$191,000−$467,000−$467,047−$187,000−$434,000−$273,121
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$94,467$94,467$93,771$103,442$103,442$147,114$234,185$229,203
Cash and short-term investments$3,016—$2,320$11,991—$17,459$104,530$29,611
Debt$1.4m$557,000$1.9m$1.8m$322,000$1.5m$1.5m$1.4m
Shareholders' equity−$5.9m−$5.9m−$5.8m−$5.3m−$5.3m−$4.8m−$4.7m−$4.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-10.8%-36.0%22.4%
Net income-28.5%-43.5%7.6%

Valuation history

At each fiscal year end

FY2013
Price to earnings0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return661%342%-70%-4%-50%-10%-72%-51%86%113%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 31 Oct 2013
  • 50-to-1 reverse split · 5 May 2008
  • 5-for-1 split · 2 Jun 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.